Next Article in Journal
Comment on Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410
Next Article in Special Issue
Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure
Previous Article in Journal
A Comprehensive Approach to Predicting the Outcomes of Transsphenoidal Endoscopic Adenomectomy in Patients with Cushing’s Disease
Previous Article in Special Issue
Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement
 
 
Review
Peer-Review Record

Biomarkers of Myocardial Injury and Remodeling in Heart Failure

J. Pers. Med. 2022, 12(5), 799; https://doi.org/10.3390/jpm12050799
by Barbara Ponikowska 1,*, Gracjan Iwanek 2,*, Agata Zdanowicz 2, Szymon Urban 2, Robert Zymliński 2, Piotr Ponikowski 2 and Jan Biegus 2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Pers. Med. 2022, 12(5), 799; https://doi.org/10.3390/jpm12050799
Submission received: 13 April 2022 / Revised: 8 May 2022 / Accepted: 13 May 2022 / Published: 16 May 2022
(This article belongs to the Special Issue Novel Biomarkers for Acute and Chronic Heart Failure)

Round 1

Reviewer 1 Report

In the current manuscript, Ponikowska et al. present a review on biomarkers of heart failure. The strength of this review is the breadth of biomarker categories covered. Overall, the manuscript is well-written and can serve as useful resource for HF researchers.

Below are my comments:

  1. The introduction is very brief. It can be expanded to include the types of biomarkers (for example, those used for diagnosis vs. those used to classify severity of disease).
  2. Discussion of classic HF biomarkers such as NT-proBNP and MR-proANP is missing.
  3. Table 1 seems to be a repetition of the biomarkers already covered in the text. Perhaps the authors can use the table to mention biomarkers not included in text.
  4. Conclusions or future directions section is lacking.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

It is an interesting review about novel biomarkers in heart failure (myocardial injury, remodeling) and  in iron metabolism.  Although the review refers to a wide spectrum of biomarkers it gives the impression that it is just a simple list of them. In my opinion, a deeper analysis and a more detailed discussion needs to be done. For which of them there is a true necessity for use in every day clinical practice? Is this a realistic target for the near future? Are there ongoing studies about their utility? Will they provide us with more information than the already used ones and will this have an impact in our therapeutic approaches? Moreover the authors have to make clear (and incorporate into the title) their choice to refer also to the iron metabolism. Of course, it is known that iron deficiency is relatively common in patients with heart failure, but there are also other common co-morbidities, like for example renal failure. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

In this revised version  the authors sufficiently improved their manuscript providing interesting and adequate details on the topic.  

Back to TopTop